Pharmacological treatment of chronic venous disorders

Phlebolymphology

Volumn 14, Issue 1, 2007, Pages 23-30

  Perrin, Michel ^a   Geroulakos, George ^a,b,c  

^a Imperial College of Science Technology and Medicine ^*  (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c EALING HOSPITAL   (United Kingdom)

Author keywords

Chronic venous disease; Flavonoids; Micronized purified flavonoid fraction (MPFF); Pain; Phlebotropic drugs

Indexed keywords

5,6 ALPHA BENZOPYRONE; AESCULUS HIPPOCASTANUM EXTRACT; ALPHA CRYPTOESCIN; BARRINGTOGENOL; BENZARONE; BETA ESCIN; CENTELLA ASIATICA EXTRACT; COUMARIN; COUMARIN DERIVATIVE; DIOSMETHIN; DIOSMIN; DOBESILATE CALCIUM; ESCIN; FLAVONOID; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; HYDROXYRUTIN; KACINPREROL; NAFTAZONE; PROTOESCIGENIN; QUERCETIN; RUSCUS EXTRACT; RUTOSIDE DERIVATIVE; SEX HORMONE; UNCLASSIFIED DRUG;

CHRONIC DISEASE; CHRONIC VENOUS DISORDER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG TARGETING; FATIGUE; HORMONAL THERAPY; HUMAN; LEG PAIN; MENSTRUAL CYCLE; MUSCLE CRAMP; PARESTHESIA; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRURITUS; RESTLESS LEGS SYNDROME; REVIEW; SYMPTOM; TEMPERATURE SENSITIVITY; VEIN DISEASE;

EID: 33845991827     PISSN: 12860107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Ramelet AA, Kern P, Perrin M, eds. Varicose veins and telangiectasias. Paris: Masson, 2003. Chapter 1 (definitions), pp. 7-16.
2. Porter JM, Moneta GL. International Consensus Committee on chronic venous disease. Reporting standards in venous disease: an update. J Vasc Surg. 1995;21:635-645.
3. Garde C, Perrin M, Chleir F, Henriel JP, et al. First meeting of review and consensus on venoactive agents on the symptoms of chronic venous disease (in French). Phlébologie. 2003;56:103-109.
4. Ramelet AA, Kern P, Perrin M, eds. Varicose veins and telangiectasias. Paris: Massen, 2003. Chapter 13 (Drug therapy) pp. 166-168.
5. Boisseau MR. Pharmacologie des médicaments veinotoniques: données actuelles sur leur mode d'action et les cibles thérapeutiques (in French). Angéiologie. 2000;52:71-77.
6. Clarke GH, Vasdekis SN, Hobbs JT, Nicolaides AN. Venous wall function in the pathogenesis of varicose veins. Surgery. 1992;111:402-408.
7. Boisseau M, Freyburger G, Busquet M, et al. Hemorheological disturbances in venous insufficiency after induced stasis. Clin Hemorheol. 1989;9:161-163.
8. Le Devehat C, Boisseau MR, Vimeux M, et al. Hemorheological factors in the pathophysiology of venous disease. Clin Hemorheol. 1989;9:861-870.
9. Taccoen A, Belcaro G, Lebard C, Zuccarelli F. Etiologies et mécanismes des varices: réalités et perspectives. STV. 1997;9:354-363.
10. Boisseau MR, Taccoen A, Garreau C, et al. Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J Cardiovasc Surg. 1995;36:369-374.
11. Saharay M, Shields DA, Georgiannos SN, et al. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 1998;15:342-349.
12. Michiels C, Arnould T, Thibaut-Vercruyssen R, et al. Perfused human saphenous veins for the study of the origin of varicose veins: role of the endothelium and of hypoxia. Int Angiol. 1997;16:135-141.
13. Michiels C, De Leener F, Arnould T, Dieu M, Remacle J. Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. Exp Cell Res. 1994;213:43-54.
14. Badier-Commander C, Couvelard A, Henin D, et al. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol. 2001;193:398-407.
15. Takase S, Pascarella L, Bergan J, Schmid-Schönbein GW. Hypertension-induced valve remodeling. J Vasc Surg. 2004;39:1329-1334.
16. Janssens D, Delaive E, Houbion A, et al. Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells. Br J Pharmacol. 2000;130:1513-1524.
17. Michiels C, Bouaziz N, Remacle J. Role of the endothelium and blood stasis in the appearance of varicose veins. Int Angiol. 2002;21:1-8.
18. Takase S, Pascarella L, Lerond L, Bergan J, Schmid-Schönbein GW. Venous hypertension. Inflammation and valve remodeling. Eur J Vasc Endovasc Surg. 2004;28:484-493.
19. Shoab SS, Porter JB, Coleridge-Smith PD. Effect of oral micronised flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg. 2000;31:456-461.
20. Agence Nationale d'Accréditation et d'Evaluation de la Santé (in French). Evaluation et suivi de la douleur chronique chez l'adulte en médecine ambulatoire (in French). www.anaes.fr.
21. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res. 1996;5:539-550.
22. Lamping DL, Abenhaim L, Kurz X, et al. Measuring quality of life and symptoms in chronic venous disorders of the leg: development and psychometric evaluation of the VEINES-Qol/SYM questionnaire. Qual Life Res. 1998;7:621-622.
23. Klyscz T, Junder M, Schanz S, et al. Quality of Life in chronic venous insufficiency (CVI). Results of a study with the newly developed Tubingen questionnaire for measuring quality of life with CVI. Hautartz. 1998;49:372-381.
24. Hachen HJ, Lorenz P. Double-blind clinical and plethysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology. 1982;33:480-487.
25. Labs KH, Degischer S, Gamba G, Jaeger KA. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized, double-blind, placebo-controlled trial. Phlebology. 2004;19:123-130.
26. Casley-Smith JR. A double blind trial of calcium dobesilate in chronic venous insufficiency. Angiology. 1988;39:853-857.
27. Pecchi S, De Franco V, Damiani P, et al. Calcium dobesilate in the treatment of primary venous insufficiency of the lower limbs. A controlled clinical study. Clin Ter. 1990;32:409-417.
28. Widmer L, Biland L, Barras JP. Doxium 500 in chronic venous insufficiency: a double-blind placebo-controlled multicentre study. Int Angiol. 1990;9:105-110.
29. Le Devehat C, Lemoine A, Roux E, et al. Aspects clinique et hemodynamique de Cyclo 3 dans l'insuffisance veineuse (in French). Angeiologie. 1984;36:119-122.
30. Sentou Y, Bernard-Fernier MF, Demarez JP, et al. Symptomatologie et pléthysmographie: parallélisme des résultats obtenus lors d'un traitment par Cyclo 3 de patients porteuses d'une insuffisance veineuse chronique (étude en double insu contre placébo). Gaz Med. 1985;92:73-77.
31. Petruzzellis V, Troccoli T, Candiani C, et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency-a double-blind, randomized, controlled study. Angiology. 2002;53:257-263.
32. Balmer A, Limoni C. A double blind placebo controlled clinical trial of Venoruton on the symptoms and signs of chronic venous insufficiency. The importance of patient selection. VASA. 1980;9:1-7.
33. MacLennan WJ, Wilson J, Rattenhuber V, et al. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology. 1994;40:45-52.
34. Chassignolle J-F, Amiel M, Lanfranchi G, et al. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle (in French). J Int Med. 1987;99:32-37.
35. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the veinolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9:67-70.
36. Cospite M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8:61-65.
37. Tsouderos Y. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Int Angiol. 1989;8:53-59.
38. Ciapponi A, Laffaire E, Roque M. Calcium dobesilate for chronic venous insufficiency: a systermatic review. Angiology. 2004;55:147-154.
39. Arceo A, Berber A, Trevino C. Clinical evaluation of the efficacy and safety of calcium dobesilate in patients with chronic venous insufficiency of the lower limbs. Angiology. 2002;53:539-544.
40. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. VASA. 1994;23:244-250.
41. Wadworth AV, Faulds D. Hydroxyethylrutosides: a review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs. 1992;44:1013-1032.
42. Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol. 2003;22:250-262.
43. Siebert U, Brach M, Sroczynski G, et al. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol. 2002;21:305-315.
44. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Arch Dermatol. 1998;134:1356-1360.
45. Geroulakos G, Nicolaides AN. Controlled studies of Daflon 500 mg in chronic venous insufficiency. Angiology. 1994;45:549-553.
46. Lyseng-Williamson KA, Perry CM. Micronised Purified Flavonoid Fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63:71-100.
47. Boada JN. Therapeutic effect of venotonics in chronic venous insufficiency. Clin Drug Invest. 1999;18:413-432.
48. Jantet G, and the RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of life improvEment with micronized Flavonoids. Angiology. 2002;53:245-256.
49. Bérard A, Kurz X, Zuccarelli F, et al. Reliability study of Leg-O-Meter, an improved tape measure device in patients with chronic venous insufficiency of the leg. Angiology. 1998;49:169-173.
50. Brijker F, Heijdra YF, Van den Elshout FJJ, et al. Volumetric measurements of peripheral oedema in clinical conditions. Clin Physio. 2000;20:56-61.
51. Vayssairat M, Maurel A, Gouny, et al. La volumétrie: une méthode précise de quantification en phlébologie (in French). J Mal Vasc. 1994;19:108-110.
52. Garde C, Nicolaides A, Guex JJ, Grondin L, et al. Consensus meeting on the action of phlebotropic drugs on chronic venous disease-related edema (in French). Phlébologie. 2004;57:7-13.
53. Stanton AWB, Northfield JW, Holroyd B, et al. Validation of an optoelectronic limb volumeter (Perometer®). Lymphology. 1997;30:77-97.
54. Perrin M, Guex JJ. Edema and leg volume: methods of assessment. Angiology. 2000;51:9-12.
55. Vayssairat M. and the French Venous Naftazone Trial Group. Placebo-controlled trial of naftazone in women with primary uncomplicated symptomatic varicose veins. Phlebology. 1997;12:17-20.
56. Diehm C, Trampish HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horse-chestnut extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347:292-294.
57. Blume J, Langenbahn H, de Champvallins M. Quantification of edema using the volometer technique;therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology. 1992;7:S37-S40.
58. Cesarone MR, Belcaro G, Brandolini R, et al. The LONFLIT4-Venoruton Study: a randomized trial-prophylaxis of flight-edema in venous patients. Angiology. 2003;54:137-142.
59. Cesarone MR, Belcaro G, Geroulakos G, et al. Flight microangiopathy on long-haul flights: prevention of edema and microcirculation alterations with Venoruton. Clin Appl Thromb Hemost. 2003;9:109-114.
60. Guilhou J-J, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology. 1997;48:77-85.
61. Glinski W, Chodynicka B, Roszkiewicz J, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology. 1999;14:151-157.
62. Roztocil K, Stvrtinova V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol. 2003;22:24-31.
63. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology. 2001;52:549-556.
64. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198-208.
65. Ottillinger B, Greeske K. Rational therapy of chronic venous insufficiency-chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord. 2001;1:5.
66. Wright DD, Franks PJ, Blair SD, et al. Oxerutins in the prevention of recurrence in chronic venous ulceration: randomized controlled trial. Br J Surg. 1991;78:1269-1270.
67. Jull A, Waters J, Arroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet. 2002;359:1550.